6 research outputs found

    Τα χρυσόβουλλα και το κανονιστικό τους περιεχόμενο στο Βυζαντινό Δίκαιο. Από την εμφάνισή τους μέχρι το 1204

    Get PDF
    Η διατριβή πραγματεύεται τα χρυσόβουλλα ως πηγή του Βυζαντινού Δικαίου. Αρχικά, στο πρώτο μέρος ερευνά γενικά τα χαρακτηριστικά των χρυσοβούλλων ως εγγράφων της αυτοκρατορικής γραμματείας, ενώ στο δεύτερο μέρος εξετάζει το ζήτημα της κανονιστικής ισχύος των χρυσοβούλλων. Η ανάλυση συνιστά μία νομική μελέτη των σχετικών ζητημάτων. Οι κύριες πηγές που μελετήθηκαν εκτείνονται κατά βάση μέχρι το 1204.The dissertation deals with the chrysobulls as a source of the Byzantine Law. The first part generally discusses the characteristics of chrysobulls as documents of the imperial chancery, whereas the second part analyzes the question of their normative power. The analysis is essentially a legal study of issues relevant to the chrysobulls. The main sources used for the study are mostly dated up to 1204 AD

    Observations on the Portrayal of the Ruler in the Novels of Leo VI

    Get PDF
    The legal texts of the Byzantine period contain elements that clearly portray the role and duties of the emperor as ruler of the State. Leo VI the Wise (886–912 AD), famous for his abundant legislative and general legal work, promulgated numerous general laws (novels). His novels promote certain “ideals”, especially equality, justice, charity and clemency, along with other principles of Christian ethics. The emperor is illustrated as a ruler who has a close relationship with God, theologizes, and philosophizes at the same time. In parallel, the emperor infiltrates the mentality of his subjects as the one responsible for the people on earth, their tireless defender, and lawmaker. Furthermore, Leo appears to consistently try to accurately determine the most appropriate, prudent, and fair solution to each problem after meticulous study. He is a philanthropist, a lenient ruler and a supporter of equality and moderation. He acts as a protector of social institutions and regulates his subjects’ lives so that they can become more well-behaved and prefer only the useful things in life. Finally, in Leo’s novels the emperor is depicted not only as the person chosen by God to rule the Empire, but also as the true embodiment of justice, dignity and divine piety

    Chrysobulls and their normative context in Byzantine law: from their appearance to 1204 AD

    No full text
    The dissertation deals with the chrysobulls as a source of the Byzantine Law. Firstly, in its first part it analyzes generally the characteristics of chrysobulls as documents of the imperial chancery, whereas in the second part it analyzes the question of their normative power. The analysis is basically a legal study of the relevant matters. The main sources that have been studied derive particularly from up to 1204 AD.Η διατριβή πραγματεύεται τα χρυσόβουλλα ως πηγή του Βυζαντινού Δικαίου. Αρχικά, στο πρώτο μέρος ερευνά γενικά τα χαρακτηριστικά των χρυσοβούλλων ως εγγράφων της αυτοκρατορικής γραμματείας, ενώ στο δεύτερο μέρος εξετάζει το ζήτημα της κανονιστικής ισχύος των χρυσοβούλλων. Η ανάλυση συνιστά μία κατά βάση νομική μελέτη των σχετικών ζητημάτων. Οι κύριες πηγές που μελετήθηκαν εκτείνονται ιδίως μέχρι το 1204

    Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

    No full text
    International audienceIn this article, the name of the GLORIA-AF investigator Anastasios Kollias was given incorrectly as Athanasios Kollias in the Acknowledgements. The original article has been corrected

    Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry

    Get PDF
    Background: Previous studies suggested potential ethnic differences in the management and outcomes of atrial fibrillation (AF). We aim to analyse oral anticoagulant (OAC) prescription, discontinuation, and risk of adverse outcomes in Asian patients with AF, using data from a global prospective cohort study. Methods: From the GLORIA-AF Registry Phase II-III (November 2011-December 2014 for Phase II, and January 2014-December 2016 for Phase III), we analysed patients according to their self-reported ethnicity (Asian vs. non-Asian), as well as according to Asian subgroups (Chinese, Japanese, Korean and other Asian). Logistic regression was used to analyse OAC prescription, while the risk of OAC discontinuation and adverse outcomes were analysed through Cox-regression model. Our primary outcome was the composite of all-cause death and major adverse cardiovascular events (MACE). The original studies were registered with ClinicalTrials.gov, NCT01468701, NCT01671007, and NCT01937377. Findings: 34,421 patients were included (70.0 ± 10.5 years, 45.1% females, 6900 (20.0%) Asian: 3829 (55.5%) Chinese, 814 (11.8%) Japanese, 1964 (28.5%) Korean and 293 (4.2%) other Asian). Most of the Asian patients were recruited in Asia (n = 6701, 97.1%), while non-Asian patients were mainly recruited in Europe (n = 15,449, 56.1%) and North America (n = 8378, 30.4%). Compared to non-Asian individuals, prescription of OAC and non-vitamin K antagonist oral anticoagulant (NOAC) was lower in Asian patients (Odds Ratio [OR] and 95% Confidence Intervals (CI): 0.23 [0.22-0.25] and 0.66 [0.61-0.71], respectively), but higher in the Japanese subgroup. Asian ethnicity was also associated with higher risk of OAC discontinuation (Hazard Ratio [HR] and [95% CI]: 1.79 [1.67-1.92]), and lower risk of the primary composite outcome (HR [95% CI]: 0.86 [0.76-0.96]). Among the exploratory secondary outcomes, Asian ethnicity was associated with higher risks of thromboembolism and intracranial haemorrhage, and lower risk of major bleeding. Interpretation: Our results showed that Asian patients with AF showed suboptimal thromboembolic risk management and a specific risk profile of adverse outcomes; these differences may also reflect differences in country-specific factors. Ensuring integrated and appropriate treatment of these patients is crucial to improve their prognosis. Funding: The GLORIA-AF Registry was funded by Boehringer Ingelheim GmbH
    corecore